Global AIDS Alliance "Treat the Children" Update Survey

The aggregate results of this survey will be published in the update
to the "Treat the Children" progress report. The report, to be
released on December 1, 2005, will document the current situation of
the treatment of children under 15 with HIV/AIDS. Please use the
most recent data available or use projections for the end of 2005.
We understand that some data may not be available and any data we do
receive is useful.

Please send the completed survey by November 18th to:

Vince DeGennaro
vdegennaro@...
1413 K Street, NW, 4th Floor
Washington, DC 20005
Tel: 202-789-0432
Fax: 202-789-0715

Definitions
Treatment with ARVs: patients receiving one or more antiretroviral
drugs for the treatment of HIV/AIDS

Medical care: prophylaxis or treatment for opportunistic infections
or AIDS-related Diseases. Examples are cotrimoxazole, tuberculosis
treatment, or Fluconazole.

WHO recommended regimen: Multi-drug regimens recommended by WHO for
the treatment of children. An example is zidovudine or stavudine +
lamivudine + nevirapine or efavirenz.

PMTCT: Prevention of mother to child transmission. PMTCT programs
attempt to decrease the intra and post-partum transmission of HIV
from an HIV-positive mother to her child by the administration of
antiretroviral drugs to both the mother and the infant.

PMTCT-plus: PMTCT programs that include the testing, care and
treatment of infants born to mothers in the PMTCT program

HIV-exposed infant: a child born to an HIV-positive mother
Confirmed HIV-positive infant: child with one or more positive DNA

PCR or RNA PCR tests if younger than 18 months, or one or more
positive antibody tests if older than 18 months and not breast
feeding for six weeks

Treatment
1. How many people are receiving ARVs through your programs
this year?

2. How many of these are children under 15? _______Infants
under 2?_______

3. How many HIV-positive people are receiving medical care?
_________

4. How many of these patients in medical care are children
under 15?_______ Infants under 2?_________

5. Are the children on ARV treatment on WHO recommended multi-
drug regimens or only one or two drugs?
___1 drug
___2 drugs
___WHO-recommended regimen

PMTCT

6. How many HIV-positive expectant mothers do you have enrolled
in PMTCT programs this year?__________________

7. How many HIV-positive expectant mothers do you have enrolled
in PMTCT-plus programs this year?__________________

8. What is the approximate rate of vertical transmission in
your PMTCT programs?

9. What services do you provide to HIV-positive mothers after
the birth?
___Education
___Counseling
___Family Planning
___ARV Treatment

10. What level of medical care is offered for HIV-exposed
infants in your PMTCT or PMTCT-plus programs? (Please indicate all
that apply)
¬¬¬¬___Antibody HIV testing
___DNA or RNA PCR HIV testing
___HIV testing and/or medical care for siblings born to the same
mother
___Cotrimoxazole prophylaxis
___Tuberculosis treatment
___Single dose ARV prophylaxis
___Long term ARV prophylaxis (more than one dose)
___ARV treatment
___Vitamin A supplementation
___Nutritional supplements
___Potable water and infant formula
___Regular visits with healthcare provider

11. What level of medical care is offered for confirmed HIV-
positive infants in your PMTCT or PMTCT-plus programs? (Please
indicate all that apply)
___Antibody HIV testing
___DNA or RNA PCR HIV testing
___HIV testing and/or medical care for siblings born to the same
mother
___Cotrimoxazole prophylaxis
___Tuberculosis treatment
___ARV treatment
___Vitamin A supplementation
___Nutritional supplements
___Potable water and infant formula
___Regular visits with healthcare provider
___Psychosocial counseling

Diagnostics
12. Approximately how many tests on HIV-exposed infants did
you perform this year?____________________________________

13. Of those tested, how many received antibody tests and how
many received DNA or RNA PCR tests?
14. What DNA or RNA PCR test do you use most often?
___Roche Amplicor DNA HIV-1 Monitor
___Roche TaqMan HIV-1 Monitor
___Abbott LcX HIV RNA Quantitative
___Bayer Versant HIV-1 RNA 3.0 Assay
___bioMerieux NucliSens EasyQ HIV-1
___Primagen Retina Rainbow

Policy
15. Do you disaggregate patient data by age groups?
___Yes
___No
If not, why not?
________________________________________________________________
6. If the prices on pediatric formulations of ARVs decreased to
levels approximately equivalent with adult formulations, would you
have the infrastructure and personnel to treat children in numbers
commensurate with pediatric infection rates?
___Yes
___No
17. Are you directly advocating to drug manufacturers for lower
prices on pediatric drugs?
___Yes
___No
18. Are you directly advocating to diagnostic manufacturers for
lower prices on diagnostics?
___Yes
___No
19. Are you directly advocating to country governments and
Ministers of Health to include children in their treatment programs?
___Yes
___No
20. What do you see as the largest obstacle to the scale up of
treatment of children for your organization?
___Lack of pediatric formulations
___Cost of pediatric formulations
___Cost of PCR diagnostic tests
___Lack of infrastructure
___Lack of pediatric-trained personnel
___Lack of funding
___Lack of political will